1-2 of 2
Daniel Levitt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pilot Phase II Study of the Lyn Kinase Inhibitor Bafetinib in Patients with Relapsed or Refractory B Cell Chronic Lymphocytic Leukemia

Tapan Kadia, Maria L Delioukina, MD, Hagop M. Kantarjian, Michael J Keating, MD, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Scott Wieland, MBA, PhD, Daniel Levitt, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2858.
https://doi.org/10.1182/blood.V118.21.2858.2858
Published: 2011
Journal Articles

A humanized non–FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

Clinical Trials & Observations
Paul A. Carpenter, Frederick R. Appelbaum, Lawrence Corey, H. Joachim Deeg, Kris Doney, Theodore Gooley, James Krueger, Paul Martin, Sandra Pavlovic, Jean Sanders, John Slattery, Daniel Levitt, Rainer Storb, Ann Woolfrey, Claudio Anasetti
Journal: Blood
Blood (2002) 99 (8): 2712–2719.
https://doi.org/10.1182/blood.V99.8.2712
Published: 2002